Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | AGXT | P21549 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17230492 | 0.89 | TAAR1 (0.59) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL8699099 | 0.89 | CHRM2 (0.63) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL30080050 | 0.87 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL723511 | 0.87 | TAAR1 (0.77) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL7901300 | 0.85 | ENPP2 (0.46) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL29986862 | 0.83 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL21002016 | 0.83 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL21002162 | 0.83 | TAAR1 (0.71) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL27655773 | 0.83 | TAAR1 (0.47) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 | |
| SCHEMBL27717492 | 0.83 | TAAR1 (0.61) | TAAR1CHRM2CHRM1CHRM3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106518750-B | Carbazole amino alcohol compound, preparation method thereof and application of carbazole amino alcohol compound in resisting parasitic diseases | 中国疾病预防控制中心寄生虫病预防控制所 | 2021-06-01 | — | — | CN | claimed |
| EP-0156224-B1 | NOVEL BENZOXATHIIN DERIVATIVE, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION | SUNTORY LIMITED (JP) | 1990-11-28 | — | — | EP | claimed |
| CN-117069725-A | Imidazopyridazine substituted benzene ring derivative, preparation method, pharmaceutical composition and application | 上海赛默罗生物科技有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-113149928-A | Fluoro-1, 2, 4-oxadiazole-containing compound and preparation method and application thereof | 青海省人民医院 | 2021-07-23 | — | — | CN | disclosed |
| CN-106518750-B | Carbazole amino alcohol compound, preparation method thereof and application of carbazole amino alcohol compound in resisting parasitic diseases | 中国疾病预防控制中心寄生虫病预防控制所 | 2021-06-01 | — | — | CN | disclosed |
| EP-3107946-B1 | A POLYISO-UREA | BASF SE (DE) | 2018-08-08 | — | — | EP | disclosed |
| EP-2500345-B1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2015-01-28 | — | — | EP | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933229-B2 | 8-azabicyclo[3.2.1]octane-8-carboxamide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| EP-2500345-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-09-19 | — | — | EP | disclosed |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-6043227-A | C11 carbamates of macrolide antibacterials | PFIZER INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5866513-A | Aryl-substituted cycloalkanes and cycloalkenes and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0768298-A1 | Aryl-substituted cycloalkanes and cycloalkenes and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
| US-4497815-A | 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients | Ozaki, Shoichiro (JP) | 1985-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | TAAR1 3268/4885CHRM2 4885/4885CHRM1 4876/4885 |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | TAAR1 4422/4885CHRM2 4885/4885CHRM1 4878/4885 |
| US-20120225876-A1 | 8-AZABICYCLO[3.2.1]OCTANE-8-CARBOXAMIDE DERIVATIVE | HDAC10, HDAC11, HDAC1 | TAAR1 744/4885CHRM2 249/4885CHRM1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.